---
title: "600062.SH (600062.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600062.SH/news.md"
symbol: "600062.SH"
name: "600062.SH"
parent: "https://longbridge.com/en/quote/600062.SH.md"
datetime: "2026-05-20T22:23:52.508Z"
locales:
  - [en](https://longbridge.com/en/quote/600062.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600062.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600062.SH/news.md)
---

# 600062.SH (600062.SH) — Related News

### [CR Double-Crane: Wholly-owned subsidiary obtains drug registration certificate for Ezetimibe tablets](https://longbridge.com/en/news/285909459.md)
*2026-05-11T08:51:28.000Z*
> CR Double-Crane's wholly-owned subsidiary, CR Sanjiu Pharmaceutical, recently received the Drug Registration Certificate

### [CR Double-Crane's subsidiary sodium-potassium-magnesium-calcium injection concentrated solution has obtained a drug registration certificate](https://longbridge.com/en/news/285695574.md)
*2026-05-08T09:15:07.000Z*
> CR Double-Crane's wholly-owned subsidiary Anhui Double-Crane Pharmaceutical recently obtained the "Drug Registration Cer

### [Left hand to right hand? No! CR Double-Crane's acquisition of 235 million has deeper meaning](https://longbridge.com/en/news/284511733.md)
*2026-04-29T07:01:10.000Z*
> CR Double-Crane acquired 100% equity of NJXB Pharmaceutical from the CR Group for 235 million yuan, aiming to address ch

### [CR Pharmaceutical's subsidiary diabetes injection has completed the Phase III clinical trial registration announcement](https://longbridge.com/en/news/284492188.md)
*2026-04-29T04:26:58.000Z*
> China Resources Pharmaceutical announced that its subsidiary "CR Double-Crane" has completed the registration and public

### [CR Double-Crane, a subsidiary of CHINARES PHARMA, acquires 100% equity of Xinbai Pharmaceutical](https://longbridge.com/en/news/284176930.md)
*2026-04-27T08:24:00.000Z*
> CR Double-Crane, a subsidiary of CHINARES PHARMA, has acquired 100% equity of Nanjing Xinbai Pharmaceutical, aiming to o

### [CHINARES PHARMA's raw material heparin calcium has received the approval notice for the chemical raw material drug listing application](https://longbridge.com/en/news/284153136.md)
*2026-04-27T04:30:00.000Z*
> The sodium heparin raw material drug of Dongying Tiandong Pharmaceutical Co., Ltd., a subsidiary of CR Double-Crane, has

### [Pregabalin "controlled substance" regulation finalized: Pfizer, CR Double-Crane and other pharmaceutical companies affected, generic drug volume release window encounters "emergency brake"](https://longbridge.com/en/news/284080819.md)
*2026-04-25T11:23:11.000Z*
> Pregabalin officially enters the "strict management" era, with the National Medical Products Administration and other ag

### [CHINARES PHARMA: CR Double-Crane's net profit for the first quarter is 501 million yuan, a year-on-year decrease of 4.08%](https://longbridge.com/en/news/283977355.md)
*2026-04-24T09:58:00.000Z*
> According to a report from Economic Information Daily on the 24th, CHINARES PHARMA announced that CR Double-Crane's net